{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:18:03Z","timestamp":1773325083010,"version":"3.50.1"},"reference-count":10,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1253\/circj.cj-17-0656","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T18:09:07Z","timestamp":1504116547000},"page":"1543-1546","source":"Crossref","is-referenced-by-count":2,"title":["Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure"],"prefix":"10.1253","volume":"81","author":[{"given":"Francesco","family":"Clemenza","sequence":"first","affiliation":[{"name":"Heart Failure Unit, ISMETT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Masson","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Giulio","family":"Conaldi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Advanced Biotechnologies, ISMETT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Di Carlo","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Advanced Biotechnologies, ISMETT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Boccanelli","sequence":"additional","affiliation":[{"name":"Cardiology Department, Quisisana Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Francesco","family":"Mureddu","sequence":"additional","affiliation":[{"name":"Cardiology Unit, San Giovanni-Addolorata Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Gonzini","sequence":"additional","affiliation":[{"name":"ANMCO Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donata","family":"Lucci","sequence":"additional","affiliation":[{"name":"ANMCO Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Di Lenarda","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, ASUI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico B.","family":"Nicolis","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Vanasia","sequence":"additional","affiliation":[{"name":"Therabel GiEnne Pharma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Latini","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the AREA IN-CHF Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. Yang RY, Rabinovich GA, Liu FT. Galectins: Structure, function and therapeutic potential. <i>Expert Rev Mol Med<\/i> 2008; 10: e17."},{"key":"2","unstructured":"2. Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis. <i>Int J Cardiol<\/i> 2015; 182: 168\u2013170."},{"key":"3","unstructured":"3. Koukoui F, Desmoulin F, Galinier M, Barutaut M, Caub\u00e8re C, Evaristi MF, et al. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists. <i>PLoS One<\/i> 2015; 10: e0119160."},{"key":"4","unstructured":"4. Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, et al. Galectin-3 in patients with heart failure with preserved ejection fraction: Results from the Aldo-DHF trial. <i>Eur J Heart Fail<\/i> 2015; 17: 214\u2013223."},{"key":"5","unstructured":"5. Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): Final results. <i>Eur J Heart Fail<\/i> 2009; 11: 68\u201376."},{"key":"6","unstructured":"6. Gupta DK, Wang TJ. Natriuretic peptides and cardiometabolic health. <i>Circ J<\/i> 2015; 79: 1647\u20131655."},{"key":"7","unstructured":"7. Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, et al. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. <i>Am Heart J<\/i> 2015; 169: 404\u2013411.e3."},{"key":"8","unstructured":"8. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: Relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. <i>Eur J Heart Fail<\/i> 2013; 15: 511\u2013518."},{"key":"9","unstructured":"9. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>Eur Heart J<\/i> 2012; 33: 2290\u20132296."},{"key":"10","unstructured":"10. Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA, et al; Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Investigators. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: Data from the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. <i>Circ Heart Fail<\/i> 2016; 9: e002551."}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/81\/10\/81_CJ-17-0656\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T00:12:43Z","timestamp":1506730363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/81\/10\/81_CJ-17-0656\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-17-0656","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}